Trial Profile

A prospective clinical study of neoadjuvant chemotherapy with sindilizumab for locally advanced gastric cancer

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 16 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sintilimab (Primary) ; Capecitabine; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

Most Recent Events

07 Jun 2022 Results (n=30 )presented at the 58th Annual Meeting of the American Society of Clinical Oncology
31 Mar 2022 New trial record
14 Mar 2022 Results (n=30) of an analysis assessing the systemic immune-inflammatory index (SII) combined with prognostic nutritional index (PNI) score to predict the efficacy of anti-programmed death 1 antibody sintilimab and XELOX regimen (capecitabine plus oxaliplatin) in the treatment of locally advanced gastric cancerpublished in the BMC Gastroenterology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com